In vitro
This study investigated whether the gastric pentadecapeptide BPC-157 and two newly designed hybrid analogs (CIARA-1 and CIARA-2) could inhibit acetylcholinesterase (AChE), an enzyme targeted in the treatment of neurodegenerative conditions such as Alzheimer's disease. The hybrid peptides were rationally designed by combining a BPC-157-derived fragment with an arginine-rich C-terminal sequence intended to enhance binding at both the catalytic and peripheral sites of AChE. Inhibitory activity was measured in vitro using a modified Ellman colorimetric assay, with kinetic parameters derived from Lineweaver-Burk plots. All three compounds showed competitive inhibition—meaning they raised the Michaelis-Menten constant (Km) without affecting maximum velocity (Vmax)—indicating direct competition with the substrate at the enzyme's active site. CIARA-1 showed the strongest inhibition (Ki = 0.24 mM; IC50 = 2.52 mM), followed by CIARA-2 and then BPC-157 itself. Results were supported by molecular docking predictions. A key limitation is that inhibitory potencies were substantially lower than those of approved AChE inhibitors. No animal or human data were included. The authors suggest these peptides represent a structural scaffold for further optimization rather than immediate therapeutic candidates.
International journal of molecular sciences · May 2026DOI ↗ Animal only
This rat study investigated whether BPC 157, a synthetic pentadecapeptide derived from a gastric protein, could protect skeletal muscle tissue from ischemia-reperfusion (I/R) injury. Twenty-four male Wistar rats were divided into four groups (n=6 each): sham surgery, BPC 157 alone, I/R injury alone, and I/R injury treated with BPC 157. I/R was induced by clamping the abdominal aorta for 45 minutes followed by 2 hours of reperfusion; BPC 157 was given intraperitoneally at the end of the ischemia period. The study measured oxidative stress markers (MDA, SOD, TAS, TOS) in serum, gene expression of inflammatory and apoptotic markers (IL-6, HIF-1α, p53, Bcl-2, Bax, Caspase-3) via qRT-PCR, and protein expression (VEGF, eNOS, IL-6, Caspase-3) via immunohistochemistry, alongside histopathological scoring. The authors report that I/R increased oxidative stress, inflammation, and apoptotic signaling, while BPC 157 treatment was associated with reduced oxidative markers, decreased inflammatory and pro-apoptotic gene expression, increased anti-apoptotic Bcl-2, partial restoration of VEGF, and improved muscle histology. Limitations include very small group sizes (n=6), use of a single dose, a single species, and no human data, restricting the generalizability of findings.
Scientific reports · May 2026DOI ↗ Review
This narrative review critically examines BPC-157 (body protection compound 157), a synthetic pentadecapeptide derived from a gastric protein fragment, through a biopharmaceutical and drug development lens rather than a purely pharmacodynamic one. The authors searched multiple major databases and patent/regulatory sources through April 2026, synthesizing evidence on physicochemical properties, pharmacokinetics, formulation challenges, and translational barriers. Key findings include: BPC-157 demonstrates unusual gastric stability and reported preclinical activity across multiple organ systems via oral, parenteral, and topical routes; a formal two-species preclinical ADME study confirmed a sub-30-minute plasma half-life, linear dose-proportional kinetics, and intramuscular bioavailability of 14–51%; a preliminary two-subject human pilot reportedly corroborated the short half-life; and a striking disconnect exists between this rapid clearance and prolonged biological effects lasting hours to days. Critically, the review identifies that no pharmaceutical-grade formulation has been developed or validated, BPC-157 lacks BCS classification data and formal excipient compatibility studies, and available human clinical data span fewer than 30 subjects across three uncontrolled pilot studies with no standardized pharmaceutical preparations. No Phase II trial has been completed. The authors conclude that the primary barrier to clinical translation is the absence of foundational pharmaceutical science, not biological activity.
Pharmaceutics · May 2026DOI ↗ Review
This structured narrative review synthesized contemporary evidence (January 2020–August 2025) on injectable peptides used in orthopaedics and sports medicine, drawing from PubMed/MEDLINE, Embase, and Web of Science. The authors identified five functional peptide classes: GLP-1 receptor agonists (e.g., semaglutide), collagen-derived injectables, regenerative peptides (e.g., BPC-157, thymosin derivatives), growth hormone secretagogues (e.g., CJC-1295, ipamorelin, tesamorelin), and related compounds. The review found that GLP-1 receptor agonists were the only class supported by reproducible randomized evidence for musculoskeletal benefit—specifically symptomatic improvement in knee osteoarthritis—attributing this primarily to weight loss and putative anti-inflammatory effects rather than proven structural cartilage modification. Collagen-derived preparations showed only preliminary signals from small, single-center prospective studies. All remaining classes were deemed investigational, carrying unresolved safety profiles, significant product quality concerns, and widespread antidoping restrictions. Risk of bias was appraised for included human trials. The authors concluded that clinical use of injectable peptides should be restricted to approved agents for established indications or rigorously designed research protocols, and that clinicians should counsel athletes about uncertain efficacy, safety risks, and antidoping consequences. The study was assigned Level V evidence and a predominantly Grade C strength of recommendation.
JBJS reviews · May 2026DOI ↗ Limited · human
This study investigated whether the synthetic peptide BPC 157 (Body Protection Compound-157) could relax human arterial tissue and whether that effect depends on the endothelium and nitric oxide (NO) signaling. Researchers used residual segments of internal mammary artery (IMA) collected from 12 patients undergoing elective coronary artery bypass graft surgery. Arterial rings were prepared with the endothelium either intact or deliberately removed, then pre-contracted with phenylephrine. Cumulative doses of BPC 157 were applied, and separate experiments used the NOS inhibitor L-NAME to assess NO involvement. The study found that BPC 157 produced a concentration-dependent reduction in arterial contraction in both endothelium-intact and endothelium-denuded rings, but relaxation was significantly greater when the endothelium was present. L-NAME pre-treatment blunted the relaxation response, implicating the endothelial NO pathway as the primary mechanism. Residual relaxation in denuded rings suggested that additional, endothelium-independent mechanisms also contribute. The authors acknowledge limitations including the small sample size (n = 12), the ex vivo nature of the tissue model, and the absence of in vivo or molecular mechanistic data, calling for further research before clinical conclusions can be drawn.
Journal of clinical medicine · May 2026DOI ↗ InsufficientPreprint
This study analyzed a large, publicly available independent testing dataset of 6,441 samples spanning fourteen peptide compounds sold through largely unregulated gray market channels directly to consumers. Compounds examined included BPC-157, semaglutide, tirzepatide, PT-141, TB-500, thymosin beta-4, and others marketed for purposes such as injury recovery, muscle growth, fat loss, and athletic performance. Researchers applied two quality acceptance frameworks — one approximating standards for 503A compounded medications and a stricter model reflecting FDA-approved drug production standards — to assess purity, measured abundance, and endotoxin burden. The study found that between 41.6% and 71.1% of samples failed to meet basic quality criteria depending on the framework applied, and measurable endotoxin contamination was detected in 15% of samples. Gray market peptides were consistently cheaper than FDA-approved alternatives, though cost differentials varied widely (e.g., 72.8% higher for tirzepatide vs. 3,850% higher for PT-141 when comparing FDA-approved options). The authors concluded that consumer-directed third-party testing improves transparency but captures only a fraction of the full safety profile relevant to patients self-administering injectable compounds. Key limitations include reliance on a secondary dataset not collected under controlled research conditions and the inability to assess many other safety dimensions beyond purity and endotoxin levels.
Unknown journal · Apr 2026DOI ↗ Review
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly marketed in sports medicine contexts, spanning both FDA-approved compounds (e.g., tesamorelin/Egrifta) and unapproved "gray market" substances (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, and others). The authors note that while many unapproved peptides show promising tissue repair and metabolic effects in animal models, rigorous human safety and efficacy data are largely absent. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses the potential for serious patient harm. Notably, the authors address the placebo effect as a possible mediator of perceived peptide efficacy and examine how social media may amplify this effect. A clinician-oriented framework is proposed to guide evidence-based patient discussions about peptide use for musculoskeletal healing and athletic performance, including consideration of alternative treatments. Key limitations include the narrative (non-systematic) review methodology and the inherently limited and heterogeneous evidence base for most compounds discussed, particularly in human populations.
Sports medicine (Auckland, N.Z.) · Apr 2026DOI ↗ ReviewPreprint
This narrative review examines the pharmacological mechanisms, safety profiles, and regulatory status of twelve peptides commonly encountered in sports medicine and athletic performance contexts, including both approved agents (e.g., tesamorelin/Egrifta, sermorelin) and unapproved "gray market" compounds (e.g., BPC-157, CJC-1295, TB-500, ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, SS-31, and thymosin beta-4). The authors note that while many unapproved peptides show promising tissue repair and metabolic outcomes in animal models, rigorous human safety and efficacy data remain scarce. The review highlights the emergence of a direct-to-consumer gray market operating outside regulatory oversight and the potential for serious patient harm. It further discusses the placebo effect as a potential mediator of perceived peptide efficacy, and how social media may amplify this effect. The authors provide a clinical framework to guide patient-provider discussions and promote evidence-based practice for musculoskeletal healing. Key limitations include the narrative (non-systematic) review design, reliance on preclinical literature for most unapproved compounds, and the absence of head-to-head human trials for the majority of agents discussed.
Unknown journal · Apr 2026DOI ↗ Review
This comprehensive narrative review examines nine therapeutic peptides with proposed applications in healthy aging and age-related conditions: tirzepatide (metabolic dysfunction), epitalon (telomere biology), GHK-Cu (dermal regeneration), BPC-157 and TB-500 (tissue repair), Semax (neuroprotection), CJC-1295 and ipamorelin (growth hormone modulation), and bremelanotide (sexual function). The authors searched PubMed, Scopus, and regulatory databases through January 2026, selecting 20 primary sources based on relevance and methodological quality. The review found that FDA-approved agents such as tirzepatide and bremelanotide have robust safety and efficacy data from large-scale trials, while investigational peptides such as epitalon, BPC-157, and TB-500 show promising signals primarily from preclinical and limited clinical studies. The authors highlight significant knowledge gaps, including the absence of long-term safety data for non-approved peptides, undefined optimal dosing regimens, unknown combination therapy effects, and lack of validated biomarkers for monitoring efficacy. The authors conclude that while therapeutic peptides offer mechanistically diverse approaches to aging hallmarks, investigational agents require rigorous clinical trial validation before clinical adoption. As a narrative review, findings are subject to selection bias and do not represent a quantitative synthesis of evidence.
Frontiers in aging · Apr 2026DOI ↗ Animal only
This review paper examines the preclinical and limited clinical evidence surrounding Body Protective Compound-157 (BPC-157), a synthetic pentadecapeptide derived from gastric proteins. The authors summarize experimental findings across a range of tissue types, noting that BPC-157 appears to support angiogenesis, collagen synthesis, fibroblast activity, and nitric oxide pathway modulation in animal models, with reported benefits to muscle, tendon, ligament, bone, and gastrointestinal healing. Anti-inflammatory effects, including reduced cytokine activity and improved microvascular integrity, as well as pain modulation via peripheral and dopaminergic mechanisms, are also described. The review notes that human research is limited to small pilot studies in musculoskeletal pain, interstitial cystitis, and intravenous administration contexts, with no major adverse effects reported. The authors acknowledge significant limitations: inconsistent preparation standards, lack of rigorous controlled trials, limited clinical validation, and ongoing regulatory restrictions. The paper concludes that BPC-157 represents a promising candidate for regenerative medicine but that robust clinical evidence is needed before therapeutic use can be recommended. As a narrative review drawing primarily on animal data, it does not establish efficacy in humans.
International journal of molecular sciences · Mar 2026DOI ↗ Animal only
This review paper examines the potential therapeutic role of BPC 157 (a synthetic 15-amino-acid peptide derived from a gastric protein) in treating severe electrolyte disturbances, drawing on a collection of animal and in-vitro experiments. The paper covers four electrolyte scenarios: (1) hyperkalemia — where BPC 157 was reported to counteract KCl overdose effects including arrhythmias, hypertension, sphincter dysfunction, and mortality in rat models; (2) hypokalemia — where BPC 157 administration (both prophylactically and therapeutically) was reported to prevent fatal outcomes, ECG abnormalities, AV block, and skeletal muscle myoclonus in furosemide-treated rats; (3) hypermagnesemia — where BPC 157 appeared to alleviate muscle weakness, brain lesions, and secondary hyperkalemia in rats; and (4) lithium intoxication — where BPC 157 was reported to promote collateral vascular pathways and resolve multiorgan failure features. In-vitro experiments using HEK293 cells suggested BPC 157 can modulate membrane potential changes induced by electrolyte imbalances. Key limitations include reliance on animal and cell-based data with no human clinical trials reported, and the review format limits independent assessment of individual study methodologies.
Current neuropharmacology · Mar 2026DOI ↗ Animal only
This review paper proposes cytoprotection as a unifying therapeutic framework to address what the authors call the "hemorrhage-thrombosis paradox" — the clinical challenge that hemorrhage and thrombosis can coexist as phase-dependent manifestations of vascular dysregulation. The paper centers on BPC 157, a stable synthetic gastric pentadecapeptide, which the authors argue can simultaneously counteract both hemorrhage and thrombosis in rodent models without directly interfering with the coagulation cascade (as assessed by aggregometry and thromboelastometry). The review synthesizes preclinical and conceptual evidence to argue that BPC 157 achieves this bidirectional vascular regulation through preservation of endothelial integrity, normalization of microcirculation, modulation of the nitric oxide system, and recruitment of collateral adaptive pathways. The authors contrast this proposed "full cytoprotection" with the "partial cytoprotection" of conventional agents such as anticoagulants, antiplatelet drugs, fibrinolytics, beta blockers, calcium channel blockers, and statins, which they contend act in isolated or unidirectional ways. The paper also discusses applications in wound healing, arrhythmia control, and normalization of Virchow's triad. Notably, the authors explicitly acknowledge that findings are predominantly preclinical and that clinical validation in humans remains necessary.
Pharmaceuticals (Basel, Switzerland) · Mar 2026DOI ↗ Animal only
This systematic review examines the use of platelet-rich plasma (PRP), growth factors (PDGF, TGF-β1, IGF-1, FGF, VEGF, BMPs), and the stable gastric pentadecapeptide BPC 157 in the treatment of tendon, ligament, and muscle injuries, as well as osteotendinous, myotendinous, and muscle-to-bone junction injuries. The authors frame these interventions under the concept of "cytoprotection," emphasizing restoration of tissue integrity. The review concludes that while growth factors delivered locally via carriers show improvements in tendon, ligament, and muscle healing, some (PDGF, TGF-β1, IGF-1) appear to have limited benefit in muscle lesions, and all show limited or no efficacy at junctional healing sites. By contrast, the authors argue that BPC 157 — proposed as a cytoprotection mediator — demonstrated consistent efficacy across tendon, ligament, muscle, and junctional injuries in rat studies, via both systemic (intraperitoneal, intragastric, drinking water) and local (topical cream) administration, without requiring carriers or scaffolds. The authors suggest translational potential for clinical use and call for further clinical trials. Key limitations include that the supporting evidence for BPC 157 is derived almost exclusively from preclinical (rat) studies, with no human clinical trial data presented.
Pharmaceuticals (Basel, Switzerland) · Feb 2026DOI ↗ Animal only
This review paper proposes "cytoprotection" as a conceptual framework for evaluating antiarrhythmic drugs — defined as the ability to suppress arrhythmias while avoiding adverse electrophysiological or systemic effects. The authors systematically compare conventional antiarrhythmics (Classes I–IV) and newer agents (late INa inhibitors, IKs enhancers, RyR2 stabilizers, gap junction modulators, and atrial-selective antiarrhythmics), characterizing them as offering only partial cytoprotection over a narrow-to-moderate range. By contrast, the stable gastric pentadecapeptide BPC 157 is hypothesized to offer broader, "full-range" cytoprotective-antiarrhythmic effects. The authors cite preclinical rodent studies showing BPC 157 restoring sinus rhythm, normalizing ECG intervals, preventing AV block, suppressing ventricular tachycardia, and attenuating ST-segment changes across diverse arrhythmia models (hypo-/hyperkalemia, ischemia-reperfusion, drug-induced). In vitro HEK293 cell data reportedly show direct membrane-stabilizing actions. The authors acknowledge that human clinical data on BPC 157 remain limited and non-cardiac in nature, and explicitly call for translational clinical investigation. The paper's central claims about BPC 157 in arrhythmias rest almost entirely on preclinical and in vitro evidence, with no controlled human cardiac trials reported.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Animal only
This rat study used Fourier Transform Infrared (FTIR) spectroscopy to investigate how the stable gastric pentadecapeptide BPC 157 affects aortic wall composition following unilateral adrenalectomy. Abdominal aortas were collected from rats at three time points (15 minutes, 5 hours, and 24 hours) after surgery. BPC 157 was administered intragastrically immediately following the procedure. Spectral data were analyzed using principal component analysis (PCA) and support vector machine discriminant analysis (SVMDA). The study found that BPC 157-treated animals showed clear and reproducible spectral separation from controls at all time points, with the most notable differences in amide I and amide II bands (associated with protein secondary structure, including collagen and elastin) and lipid C-H stretching bands (associated with membrane integrity). The authors interpreted these signatures as consistent with early extracellular matrix reinforcement and membrane preservation in the vascular wall. Limitations include the exclusive use of an animal model, a small number of time points, and the indirect, spectroscopic nature of the outcome measures, which do not constitute direct functional or histological endpoints. No human data were reported.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Animal only
This 7-day rat study investigated the course of surgically created tracheocutaneous fistulas and whether the pentadecapeptide BPC 157 could promote healing, with a focus on the nitric oxide (NO) system's role. Rats with tracheocutaneous fistulas displayed severe respiratory distress, including open-mouth breathing, abdominal "heaving," cyanosis, abundant fistula secretion, weight loss, failed skin and tracheal wound healing, a well-formed fistulous tract, and tracheal shrinking below the fistula site. Tissue analyses showed decreased NO levels and increased malondialdehyde (MDA), a marker of oxidative stress. BPC 157, administered either intraperitoneally or in drinking water, was reported by the authors to accelerate fistula closure, improve macro- and microscopic healing of skin and tracheal defects, reduce respiratory distress signs, and counteract the NO and MDA changes observed in untreated controls. Using a "triple NO-agent" approach (L-NAME to block NO synthesis, L-arginine to enhance it, or both combined), the study further reported that BPC 157 could override L-NAME-induced worsening, enhance L-arginine-induced improvement, and restore healing even under combined NO immobilization. Key limitations include the exclusive use of an animal model, small experimental groups typical of rat studies, and the absence of human data.
Pharmaceuticals (Basel, Switzerland) · Jan 2026DOI ↗ Review
This narrative review examines the potential role of therapeutic peptides in orthopaedic care, synthesizing preclinical and mechanistic literature across several peptide classes. The authors categorize peptides by their primary proposed function: wound-healing agents (BPC-157, TB-500, GHK-Cu), growth hormone secretagogues (ipamorelin, CJC-1295, tesamorelin, sermorelin, AOD-9604), recovery-enhancing peptides (epithalon, delta sleep-inducing peptide, pinealon), and neuroactive peptides (selank, semax, dihexa). The review describes how these compounds are theorized to interact with signaling pathways—including PI3K/Akt, mTOR, MAPK, TGF-β, and AMPK—to promote tissue regeneration, resolve inflammation, and support neuromuscular recovery. The authors acknowledge that, while preclinical evidence is promising, robust human clinical trial data are largely absent, representing a significant gap in the literature. Limitations include the review's reliance on animal and in vitro studies, the absence of a systematic search methodology, and the lack of direct clinical evidence supporting efficacy or safety in human orthopaedic populations. The authors call for future controlled trials to validate these mechanistic findings in clinical settings.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · Jan 2026DOI ↗ Review
This narrative review, aimed at orthopaedic and sports medicine physicians, synthesizes the existing biochemical and clinical literature on six commonly marketed injectable therapeutic peptides: BPC-157, TB-4, TB-500, CJC-1295 + ipamorelin, tesamorelin, and GHK-Cu. The authors conducted a PubMed literature search and evaluated evidence across preclinical and clinical settings. Key findings attributed to the reviewed studies include: BPC-157 showed potential in tendon and muscle repair in preclinical models, with one human case series reporting pain reduction after intra-articular knee injection, though that study had significant methodological limitations and no control group. TB-4 and TB-500 demonstrated angiogenesis and tissue repair effects in animal models, but no human orthopaedic data were identified, and both are banned in sport. CJC-1295 combined with ipamorelin improved muscle tension in a murine glucocorticoid-induced muscle loss model only. Tesamorelin holds FDA approval for HIV-associated lipodystrophy but lacks orthopaedic evidence. GHK-Cu showed wound healing and anti-inflammatory properties preclinically, with no clinical musculoskeletal data. The authors conclude that indications, safety profiles, and dosing for all these peptides remain undefined for orthopaedic use, and robust human trials are needed before clinical recommendations can be made.
The American journal of sports medicine · Jan 2026DOI ↗ ReviewPreprint
This review paper examines the pharmacological mechanisms, safety profiles, and regulatory status of both approved and unapproved peptide therapies relevant to sports medicine, musculoskeletal injury recovery, and athletic performance enhancement. The compounds reviewed span a wide spectrum — from FDA-approved agents such as tesamorelin and sermorelin, to gray-market compounds including BPC-157, TB-500, CJC-1295, Ipamorelin, AOD-9604, FS-344, GHK-Cu, MOTS-C, and SS-31. The authors note that while many unapproved peptides show promising results in preclinical and animal models — including favorable tissue repair and metabolic effects — rigorous human safety and efficacy data remain scarce. The review highlights a growing direct-to-consumer gray market operating outside regulatory oversight and discusses how social media may amplify perceived benefits through placebo-related mechanisms. The paper also offers a clinical framework to guide patient conversations and support evidence-based decision-making. Key limitations include the inherent constraints of a narrative review design, reliance on heterogeneous preclinical data for unapproved compounds, and the absence of controlled human trials for most of the highlighted peptides.
Unknown journal · Dec 2025DOI ↗ In vitroPreprint
This paper proposes a molecular mechanism for BPC-157, a synthetic 15-amino-acid peptide previously studied in preclinical models for regenerative and cytoprotective effects. The authors hypothesize — based on computational structural modeling and in silico docking — that BPC-157 adopts a polyproline II (PPII) helix conformation and engages the SH3 domains of Src family kinases (c-Src, Yes, Fyn). The proposed interaction is suggested to relieve autoinhibition of these kinases, potentially activating downstream FAK-ERK and PI3K-Akt signaling pathways. To build a tool for future experimental testing, the authors engineered an mCherry-BPC157₂ fusion protein, encoded it in a baculovirus vector, and expressed it in insect (Sf9) cells. Expression was confirmed by fluorescence imaging and western blot at the expected ~31 kDa size. Importantly, this study does not include human subjects, animal experiments, or in vitro binding assays — the core mechanistic claims rest entirely on computational modeling. The fusion protein work is a proof-of-concept for a future experimental reagent. Findings should be interpreted as hypothesis-generating only.
Unknown journal · Dec 2025DOI ↗